Cost-effectiveness of oral nirmatrelvir/ritonavir in patients at high risk for progression to severe COVID-19 in the United States
Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of patients with mild-to-moderate COVID-19 at high risk for disease progression to severe illness. We estimated the cost-effectiveness of NMV/r versus best supportive care for patients with mild-to-moderate COVID-19 at high risk for progression to severe illness from a US health sector perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Josh Carlson, Volker Foos, Adam Kasle, Tendai Mugwagwa, Florin Draica, Timothy Lee Wiemken, Jennifer L. Nguyen, Ashley Cha-Silva, Kristen Migliaccio-Walle, Mendy Dzingina Source Type: research
EE337 Cost-Effectiveness of Nirmatrelvir/Ritonavir in High-Risk Swedish Adults Including Post-Acute COVID Syndrome (PACS) From a Societal Perspective
This study assessed the cost-effectiveness of nirmatrelvir/ritonavir compared to standard of care (SoC) from a societal perspective in Sweden. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Aldv én, M. Kądziela, C. Gerdesköld, A. Arash Rahimi, F. Nilsson Source Type: research
EE488 Budget Impact Analysis of Oral Treatment With Nirmaltrevir+Ritonavir for COVID-19 in Argentina
to estimate the budget impact (BI) of the oral treatment, nirmaltrevir+ritonavir, for mild-to-moderate coronavirus disease in adults who are at risk of progression to severe COVID-19 for the whole Argentinean health system. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Rey-Ares, M.F. Viozzi, C. Vega, J. Elgart, M.L. Glancszpigel Source Type: research
EE644 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the US
Nirmatrelvir/ritonavir (NMV/r) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19. NMV/r has also been authorized for emergency use by FDA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Sandin, D. Veenstra, M. Dzingina, M. Vankelegom, S. Sullivan, D. Campbell, C. Ma, C. Harrison, F. Draica, T.L. Wiemken, T. Mugwagwa Source Type: research
HTA116 Cost-Effectiveness of Nirmatrelvir/Ritonavir for the Treatment of Outpatient Sars-Cov-2 in Adult Patients at Risk for Developing Severe Disease in Greece
The objective of this cost effectiveness analysis is to assess the health and economic impact, associated with the introduction of nirmatrelvir/ritonavir as an antiviral treatment for SARS-CoV-2 for adult patients in Greece who do not require supplemental oxygen and who are at increased risk of developing severe disease. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Kalogeropoulou, M. Barmpouni, V. Grammelis, A. Rousakis, A. Livieratos, D. Paraskevis, O. Zisimopoulou Source Type: research
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
CONCLUSIONS: Low-certainty evidence suggests nirmatrelvir/ritonavir reduces the risk of all-cause mortality and hospital admission or death in high-risk, unvaccinated COVID-19 outpatients infected with the Delta variant of SARS-CoV-2. There is low- to moderate-certainty evidence of the safety of nirmatrelvir/ritonavir. Very low-certainty evidence exists regarding the effects of nirmatrelvir/ritonavir on all-cause mortality and viral clearance in mildly to moderately affected, mostly unvaccinated COVID-19 inpatients infected with the Omicron variant of SARS-CoV-2. Insufficient and inconsistent information prevents the asses...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Stefanie Reis Maria-Inti Metzendorf Rebecca Kuehn Maria Popp Ildiko Gagyor Peter Kranke Patrick Meybohm Nicole Skoetz Stephanie Weibel Source Type: research
Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients
CONCLUSION: The transition to TAF/FTC/BIC demonstrated good treatment potency. Furthermore, this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios, providing clinical evidence supporting the stable conversion to TAF/FTC/BIC for HAART-experienced patients.PMID:38032036 | DOI:10.1097/CM9.0000000000002939 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - November 30, 2023 Category: General Medicine Authors: Jiang Xiao Guiju Gao Yi Ding Jialu Li Chengyu Gao Qiuhua Xu Liang Wu Hongyuan Liang Liang Ni Fang Wang Yujiao Duan Di Yang Hongxin Zhao Source Type: research
Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients
CONCLUSION: The transition to TAF/FTC/BIC demonstrated good treatment potency. Furthermore, this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios, providing clinical evidence supporting the stable conversion to TAF/FTC/BIC for HAART-experienced patients.PMID:38032036 | DOI:10.1097/CM9.0000000000002939 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - November 30, 2023 Category: General Medicine Authors: Jiang Xiao Guiju Gao Yi Ding Jialu Li Chengyu Gao Qiuhua Xu Liang Wu Hongyuan Liang Liang Ni Fang Wang Yujiao Duan Di Yang Hongxin Zhao Source Type: research
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
CONCLUSIONS: Low-certainty evidence suggests nirmatrelvir/ritonavir reduces the risk of all-cause mortality and hospital admission or death in high-risk, unvaccinated COVID-19 outpatients infected with the Delta variant of SARS-CoV-2. There is low- to moderate-certainty evidence of the safety of nirmatrelvir/ritonavir. Very low-certainty evidence exists regarding the effects of nirmatrelvir/ritonavir on all-cause mortality and viral clearance in mildly to moderately affected, mostly unvaccinated COVID-19 inpatients infected with the Omicron variant of SARS-CoV-2. Insufficient and inconsistent information prevents the asses...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Stefanie Reis Maria-Inti Metzendorf Rebecca Kuehn Maria Popp Ildiko Gagyor Peter Kranke Patrick Meybohm Nicole Skoetz Stephanie Weibel Source Type: research
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
CONCLUSIONS: Low-certainty evidence suggests nirmatrelvir/ritonavir reduces the risk of all-cause mortality and hospital admission or death in high-risk, unvaccinated COVID-19 outpatients infected with the Delta variant of SARS-CoV-2. There is low- to moderate-certainty evidence of the safety of nirmatrelvir/ritonavir. Very low-certainty evidence exists regarding the effects of nirmatrelvir/ritonavir on all-cause mortality and viral clearance in mildly to moderately affected, mostly unvaccinated COVID-19 inpatients infected with the Omicron variant of SARS-CoV-2. Insufficient and inconsistent information prevents the asses...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Stefanie Reis Maria-Inti Metzendorf Rebecca Kuehn Maria Popp Ildiko Gagyor Peter Kranke Patrick Meybohm Nicole Skoetz Stephanie Weibel Source Type: research
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
CONCLUSIONS: Low-certainty evidence suggests nirmatrelvir/ritonavir reduces the risk of all-cause mortality and hospital admission or death in high-risk, unvaccinated COVID-19 outpatients infected with the Delta variant of SARS-CoV-2. There is low- to moderate-certainty evidence of the safety of nirmatrelvir/ritonavir. Very low-certainty evidence exists regarding the effects of nirmatrelvir/ritonavir on all-cause mortality and viral clearance in mildly to moderately affected, mostly unvaccinated COVID-19 inpatients infected with the Omicron variant of SARS-CoV-2. Insufficient and inconsistent information prevents the asses...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Stefanie Reis Maria-Inti Metzendorf Rebecca Kuehn Maria Popp Ildiko Gagyor Peter Kranke Patrick Meybohm Nicole Skoetz Stephanie Weibel Source Type: research
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
CONCLUSIONS: Low-certainty evidence suggests nirmatrelvir/ritonavir reduces the risk of all-cause mortality and hospital admission or death in high-risk, unvaccinated COVID-19 outpatients infected with the Delta variant of SARS-CoV-2. There is low- to moderate-certainty evidence of the safety of nirmatrelvir/ritonavir. Very low-certainty evidence exists regarding the effects of nirmatrelvir/ritonavir on all-cause mortality and viral clearance in mildly to moderately affected, mostly unvaccinated COVID-19 inpatients infected with the Omicron variant of SARS-CoV-2. Insufficient and inconsistent information prevents the asses...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Stefanie Reis Maria-Inti Metzendorf Rebecca Kuehn Maria Popp Ildiko Gagyor Peter Kranke Patrick Meybohm Nicole Skoetz Stephanie Weibel Source Type: research
Therapeutic drug monitoring mediated by the cooperative chemical and electromagnetic effects of Ti < sub > 3 < /sub > C < sub > 2 < /sub > T < sub > X < /sub > modified with Ag nanocubes
Biosens Bioelectron. 2023 Nov 21;245:115844. doi: 10.1016/j.bios.2023.115844. Online ahead of print.ABSTRACTIt is pivotal for the credible utilization of surface-enhanced Raman scattering (SERS) technique in clinical drug monitoring to exploit versatile substrates with dependable quantitative detection and robust recognition abilities. Herein, a commendable electromagnetic-chemical dual-enhancement SERS substrate dependent on Ti3C2TX and Ag nanocubes (Ag NCs) was fabricated for the precise quantification of ritonavir and ibrutinib in serum. Specifically, it was revealed that numerous electromagnetic "hotspots" emerged near...
Source: Biosensors and Bioelectronics - November 24, 2023 Category: Biotechnology Authors: Danni Xue Xing Dai Jialong Zhao Jiayao Zhang Huan Liu Kui Liu Tao Xu Chenjie Gu Xingfei Zhou Tao Jiang Source Type: research
Therapeutic drug monitoring mediated by the cooperative chemical and electromagnetic effects of Ti < sub > 3 < /sub > C < sub > 2 < /sub > T < sub > X < /sub > modified with Ag nanocubes
Biosens Bioelectron. 2023 Nov 21;245:115844. doi: 10.1016/j.bios.2023.115844. Online ahead of print.ABSTRACTIt is pivotal for the credible utilization of surface-enhanced Raman scattering (SERS) technique in clinical drug monitoring to exploit versatile substrates with dependable quantitative detection and robust recognition abilities. Herein, a commendable electromagnetic-chemical dual-enhancement SERS substrate dependent on Ti3C2TX and Ag nanocubes (Ag NCs) was fabricated for the precise quantification of ritonavir and ibrutinib in serum. Specifically, it was revealed that numerous electromagnetic "hotspots" emerged near...
Source: Biosensors and Bioelectronics - November 24, 2023 Category: Biotechnology Authors: Danni Xue Xing Dai Jialong Zhao Jiayao Zhang Huan Liu Kui Liu Tao Xu Chenjie Gu Xingfei Zhou Tao Jiang Source Type: research
Homogeneous liquid –liquid microextraction coupled with HPLC/DAD for determination of nirmatrelvir and ritonavir as COVID-19 combination therapy in human plasma
The study reports the development of a high-performance liquid chromatography/diode array detection method to measure the levels of nirmatrelvir and ritonavir in human plasma. These two antiviral medications a... (Source: Chemistry Central Journal)
Source: Chemistry Central Journal - November 24, 2023 Category: Chemistry Authors: Inas A. Abdallah, Sherin F. Hammad, Alaa Bedair and Fotouh R. Mansour Tags: Research Source Type: research
